SCHEMBL164555

SCHEMBL164555

C[C@@](N)(CCC(N)=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.54
ARG1 P05089 1/20 0.48
ARG2 P78540 1/20 0.48
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 2/20 0.39
THRB P10828 1/20 0.39
BLM P54132 3/20 0.38
NOS2 P35228 5/20 0.38
NOS1 P29475 3/20 0.38
NOS3 P29474 1/20 0.38
ALOX15 P16050 2/20 0.35
PMP22 Q01453 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
EGFR P00533 1/20 0.35
FYN P06241 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159588 1.00 GGT1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL574414 1.00 GGT1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL200536 0.83 ALDH1A1 (0.56) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL200537 0.83 ALDH1A1 (0.56) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL473835 0.83 ALDH1A1 (0.56) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL8687592 0.82 GGT1 (0.65) GGT1ARG1ARG2ALDH1A1KMT2A
Water SCHEMBL434488 0.81 ALDH1A1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
Water SCHEMBL10780975 0.81 ALDH1A1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
Water SCHEMBL10780977 0.81 ALDH1A1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL3419878 0.80 ARG1 (0.38) GGT1ARG1ARG2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US claimed
EP-1718602-A4 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2007-12-12 EP claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
EP-1718602-A1 THERAPEUTIC AND CARRIER MOLECULES Peplin Biolipids Pty Ltd. (AU) 2006-11-08 EP claimed
US-7070969-B1 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis THE UNIVERSITY OF QUEENSLAND (AU) 2006-07-04 US claimed
WO-2005073164-A1 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2005-08-11 WO claimed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
CN-120202191-A Inhibitors of prostate specific membrane antigen and uses thereof 上海先通生物科技有限公司 2025-06-24 CN disclosed
WO-2025091087-A1 BISPECIFIC PROTEINS MONASH UNIVERSITY (AU) 2025-05-08 WO disclosed
CN-119816487-A FC conjugates comprising CD73 inhibitors and uses thereof 奇达拉治疗公司 2025-04-11 CN disclosed
WO-2025064873-A2 COMPOSITIONS AND METHODS FOR TREATING CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2025-03-27 WO disclosed
CN-119367342-A CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation 奥迈科斯治疗公司 2025-01-28 CN disclosed
CN-114980933-B Compositions and methods for treating viral infections 奇达拉治疗公司 2025-01-07 CN disclosed
WO-1997015663-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-05-01 WO disclosed
WO-1997012037-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-04-03 WO disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215895-A1 Therapeutic and carrier molecules PHKG1, PHKG2, DGKB GGT1 1211/4885ARG1 4434/4885ARG2 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.